<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04822272</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2021/02</org_study_id>
    <nct_id>NCT04822272</nct_id>
  </id_info>
  <brief_title>MagneThermoPro : Magnetic Resonance Thermography of Human Prostate</brief_title>
  <acronym>ThermoPro</acronym>
  <official_title>MagneThermoPro : Magnetic Resonance Thermography of Human Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this project is to offer a very innovative solution for measuring&#xD;
      temperature variations in MRI on the prostate. Multiparametric prostate MRI can detect target&#xD;
      lesions, on which targeted biopsies are then performed. The use of a temperature mapping on&#xD;
      the prostate in MRI would make it possible to evaluate a focal treatment of the prostate by&#xD;
      laser under MRI guidance&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prostate MRI has become the benchmark examination to search for tumor targets, thanks to a&#xD;
      multi-parameter protocol, including T2 sequences, diffusions, and T1 with gadolinium&#xD;
      injection. A PIRADS prognostic score is performed on the different sequences and if the&#xD;
      lesions are at high risk of malignancy (PIRADS 4 and 5), a targeted biopsy is performed.&#xD;
      Minimally invasive ablations called focal treatments are developing more and more: HIFU,&#xD;
      cryotherapy, laser, etc. Ultrasound remains the most widespread examination due to its&#xD;
      availability, but with less sensitivity than MRI. Ablations are performed under ultrasound&#xD;
      with fusion of MRI images In order to assess the ablation area under MRI, the measurement of&#xD;
      temperature variations appears necessary to verify the effectiveness of ablation and the&#xD;
      lesion volume. Temperature maps are feasible in cardiac MRI during radiofrequency. The&#xD;
      thermal mapping MRI sequence is performed in cardiac MRI at the IHU in Bordeaux.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 9, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>MRI sequence of 5 to 10 minutes to measure the variation of temprerature in the prostate</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>signal noise ratio</measure>
    <time_frame>End of MRI exam (hour 1)</time_frame>
    <description>the evaluation of the signal on the thermometry sequence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>temperature variance</measure>
    <time_frame>End of MRI exam (hour 1)</time_frame>
    <description>temperature variance measurements in a region of interest of the prostate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>spatial distortion measurement</measure>
    <time_frame>End of MRI exam (hour 1)</time_frame>
    <description>spatial distortion measurement</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer Diagnosis</condition>
  <arm_group>
    <arm_group_label>Thermometry MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRI sequence of 5 to 10 minutes to measure the variation of temprerature in the prostate</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI thermometry</intervention_name>
    <description>MRI sequence of 5 to 10 minutes to measure the variation of temprerature in the prostate</description>
    <arm_group_label>Thermometry MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years old&#xD;
&#xD;
          -  Patient with indication of injected multi-parameter MRI for the diagnosis of prostate&#xD;
             cancer.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
          -  Person affiliated or beneficiary of health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MRI contraindications (Pace Maker, metallic foreign body, metallic heart valve).&#xD;
&#xD;
          -  Contraindication to gadolinium salt,&#xD;
&#xD;
          -  Patient under legal protection&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clement Marcelin, MD</last_name>
    <phone>+335 56 79 55 99</phone>
    <email>clement.marcelin@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bruno Quesson, PhD</last_name>
    <email>bruno.quesson@u-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Clement Marcelin, MD</last_name>
      <phone>+335 56 79 55 99</phone>
      <email>clement.marcelin@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>prostate</keyword>
  <keyword>thermometry</keyword>
  <keyword>laser</keyword>
  <keyword>ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

